This application addresses broad Challenge Area (15): Translational Science and specific Challenge Topic, 15- DK-103: Translate discovery of new molecules and pathways in pathogenesis of NIDDK diseases into potential therapies, diagnostics, or research tools. Polycystic kidney disease is one of the most common human genetic diseases and a major cause of chronic renal insufficiency requiring dialysis or kidney transplantation. There is compelling evidence that in autosomal dominant polycystic kidney disease (ADPKD) progressive fluid accumulation into cysts requires chloride secretion by the cystic fibrosis transmembrane conductance regulator protein (CFTR), a cAMP-regulated chloride channel, which, when mutated, causes the genetic disease cystic fibrosis. Cyst growth in ADPKD requires fluid secretion into the cyst lumen coupled with epithelial cell hyperplasia. CFTR inhibitor 'antisecretory therapy'may offer life-long therapy to prolong kidney survival in ADPKD. At present there is no FDA-approved drug to prolong kidney survival in ADPKD. Our laboratory has identified, by high-throughput screening, two classes of small-molecule CFTR inhibitors, thiazolidinones and glycine hydrazides, which, in published proof-of-concept studies, are effective in preventing cyst fluid accumulation in ADPKD models. A large screen recently yielded a third class of pyrimido-pyrrolo-quinoxaline (PPQ) CFTR inhibitors that have unique properties and are very potent and effective in preventing cyst expansion in kidney organ culture models.
The first aim of this application is to select, using kidney organ culture and pkd1 knockout mouse models, the best small-molecule CFTR inhibitors for preventing cyst growth in ADPKD. CFTR inhibitors of the thiazolidinone, glycine hydrazide and PPQ classes will be evaluated. The goal of this aim will be to select the best inhibitor(s) of each class that are effective in preventing cyst growth, non-toxic, and orally bioavailable.
The second aim will be to prioritize the best CFTR inhibitors selected in the first aim, based on analyses of pharmacokinetics, ADME (absorption, distribution, metabolism, excretion), toxicity and mutagenic potential. The goal is to select the best one or two compounds for further pre-clinical development.

Public Health Relevance

Polycystic kidney disease is one of the most common genetic diseases and a major cause of kidney failure leading to dialysis or kidney transplantation. New drug candidates, called CFTR inhibitors, discovered by our laboratory will be tested for their potential in treating polycystic kidney disease using culture and animal models. This new form of therapy might ultimately prolong kidney function in polycystic kidney disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
NIH Challenge Grants and Partnerships Program (RC1)
Project #
5RC1DK086125-02
Application #
7938623
Study Section
Special Emphasis Panel (ZRG1-DKUS-A (58))
Program Officer
Ketchum, Christian J
Project Start
2009-09-25
Project End
2012-07-31
Budget Start
2010-08-01
Budget End
2012-07-31
Support Year
2
Fiscal Year
2010
Total Cost
$498,694
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Owens, Gregory P; Ritchie, Alanna; Rossi, Andrea et al. (2015) Mutagenesis of the aquaporin 4 extracellular domains defines restricted binding patterns of pathogenic neuromyelitis optica IgG. J Biol Chem 290:12123-34
Asavapanumas, Nithi; Ratelade, Julien; Verkman, A S (2014) Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG. Acta Neuropathol 127:539-51
Smith, Alex J; Jin, Byung-Ju; Ratelade, Julien et al. (2014) Aggregation state determines the localization and function of M1- and M23-aquaporin-4 in astrocytes. J Cell Biol 204:559-73
Asavapanumas, Nithi; Ratelade, Julien; Papadopoulos, Marios C et al. (2014) Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. J Neuroinflammation 11:16
Esteva-Font, Cristina; Phuan, Puay-Wah; Anderson, Marc O et al. (2013) A small molecule screen identifies selective inhibitors of urea transporter UT-A. Chem Biol 20:1235-44
Ratelade, Julien; Asavapanumas, Nithi; Ritchie, Alanna M et al. (2013) Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol 126:699-709
Snyder, David S; Tradtrantip, Lukmanee; Battula, Sailaja et al. (2013) ABSOLUTE CONFIGURATION AND BIOLOGICAL PROPERTIES OF ENANTIOMERS OF CFTR INHIBITOR BPO-27. ACS Med Chem Lett 4:456-459
Tradtrantip, Lukmanee; Ratelade, Julien; Zhang, Hua et al. (2013) Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 73:77-85
Verkman, A S; Phuan, Puay-Wah; Asavapanumas, Nithi et al. (2013) Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol 23:684-95
Zhang, Hua; Verkman, A S (2013) Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 123:2306-16

Showing the most recent 10 out of 49 publications